Schiess, M., Urbanczik, R
Bloating or Discomfort Backed-up food and waste in the gastrointestinal tract can lead to bloating, abdominal distension, and discomfort in people experiencing constipation during Ozempic therapy
Ingredients/Material Onsen-Sui, Water, Butylene Glycol, Glycerin, Propylene Glycol Dicaprylate, Titanium Dioxide, Cyclopentasiloxane, Sodium Hyaluronate, Pentaerythrityl Tetraethylhexanoate, Niacinamide, PEG-10 Dimethicone, Dimethicone, Cyclohexasiloxane, 1,2-Hexanediol, Phenyl Trimethicone, Caprylyl Glycol, Ammonium Acryloyldimethyltaurate/VP Copolymer, Sodium Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Glutathione, Persea Gratissima (Avocado) Oil, Allantoin, Pentylene Glycol, Isohexadecane, Thuja Orientalis Leaf Extract, Zanthoxylum Schinifolium Leaf Extract, Polygonum Cuspidatum Root Extract, Aloe Barbadensis Leaf Powder, Centella Asiatica Extract, Scutellaria Baicalensis Root Extract, Camellia Sinensis Leaf Extract, Glycyrrhiza Glabra Root Extract, Chamomilla Recutita Flower Extract, Rosmarinus Officinalis Leaf Extract, Simmondsia Chinensis Seed Oil, Ethylhexylglycerin, Adenosine, Dipotassium Glycyrrhizate, Polysorbate 80, Aspalathus Linearis Extract For orders shipping to the United States, required U.S
PMID 18841274
During Ozempic clinical trials, 20% of participants experienced nausea, and 10% noted occurrences of vomiting, which are both symptoms prevalent in cases of gastroparesis
Retatrutide is an investigational triple agonist peptide (GIP, GLP-1, and glucagon receptor) currently under clinical development for the management of obesity and type 2 diabetes
